Spaces:
Sleeping
Sleeping
File size: 51,908 Bytes
6aa59d5 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 1,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/IPython/core/interactiveshell.py:3577: LangChainDeprecationWarning: As of langchain-core 0.3.0, LangChain uses pydantic v2 internally. The langchain_core.pydantic_v1 module was a compatibility shim for pydantic v1, and should no longer be used. Please update the code to import from Pydantic directly.\n",
"\n",
"For example, replace imports like: `from langchain_core.pydantic_v1 import BaseModel`\n",
"with: `from pydantic import BaseModel`\n",
"or the v1 compatibility namespace if you are working in a code base that has not been fully upgraded to pydantic 2 yet. \tfrom pydantic.v1 import BaseModel\n",
"\n",
" exec(code_obj, self.user_global_ns, self.user_ns)\n"
]
}
],
"source": [
"from langchain_community.agent_toolkits import create_sql_agent\n",
"from langchain_openai import ChatOpenAI\n",
"from langchain_groq import ChatGroq\n",
"from langchain_core.prompts import ChatPromptTemplate\n",
"from langchain_core.pydantic_v1 import BaseModel, Field\n",
"import pandas as pd\n",
"from pydantic import BaseModel, Field\n",
"\n",
"from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
"from langchain_community.vectorstores import Chroma\n",
"from langchain.embeddings import HuggingFaceEmbeddings\n",
"from langchain_core.runnables import RunnablePassthrough\n",
"from langchain_core.output_parsers import StrOutputParser\n",
"\n",
"\n",
"gpt = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0)\n",
"#agent_gpt_executor = create_sql_agent(gpt, db=db, agent_type=\"tool-calling\", verbose=True)\n",
"\n",
"## make database\n",
"from langchain_community.utilities import SQLDatabase\n",
"from sqlalchemy import create_engine\n",
"\n",
"from langchain.prompts import ChatPromptTemplate\n",
"from langchain.schema import SystemMessage\n",
"from langchain_core.prompts import MessagesPlaceholder\n",
"#agent_groq_executor = create_sql_agent(llm, db=db, agent_type=\"tool-calling\", verbose=True)\n",
"\n",
"from OpenAITools.FetchTools import fetch_clinical_trials, fetch_clinical_trials_jp\n",
"from OpenAITools.CrinicalTrialTools import QuestionModifierEnglish, TumorNameExtractor, SimpleClinicalTrialAgent,GraderAgent,LLMTranslator\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"#### Define LLMS"
]
},
{
"cell_type": "code",
"execution_count": 2,
"metadata": {},
"outputs": [],
"source": [
"gpt = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0)\n",
"#agent_gpt_executor = create_sql_agent(gpt, db=db, agent_type=\"tool-calling\", verbose=True)\n",
"groq = ChatGroq(model_name=\"llama3-70b-8192\", temperature=0)\n",
"#agent_groq_executor = create_sql_agent(groq, db=db, agent_type=\"tool-calling\", verbose=True)"
]
},
{
"cell_type": "code",
"execution_count": 3,
"metadata": {},
"outputs": [],
"source": [
"age = \"65\"\n",
"sex =\"男性\"\n",
"tumor_type =\"胃癌\"\n",
"#tumor_type = \"gastric cancer\"\n",
"GeneMutation =\"HER2\"\n",
"Meseable = \"有り\"\n",
"Biopsiable = \"有り\"\n",
"NCTID = 'NCT06441994'\n"
]
},
{
"cell_type": "code",
"execution_count": 4,
"metadata": {},
"outputs": [],
"source": [
"def generate_ex_question(age, sex, tumor_type, GeneMutation, Meseable, Biopsiable):\n",
" # GeneMutationが空の場合はUnknownに設定\n",
" gene_mutation_text = GeneMutation if GeneMutation else \"Unknown\"\n",
" \n",
" # MeseableとBiopsiableの値をYes, No, Unknownに変換\n",
" meseable_text = (\n",
" \"Yes\" if Meseable == \"有り\" else \"No\" if Meseable == \"無し\" else \"Unknown\"\n",
" )\n",
" biopsiable_text = (\n",
" \"Yes\" if Biopsiable == \"有り\" else \"No\" if Biopsiable == \"無し\" else \"Unknown\"\n",
" )\n",
" \n",
" # 質問文の生成\n",
" ex_question = f\"\"\"{age}歳{sex}の{tumor_type}患者さんはこの治験に参加することができますか？\n",
"判明している遺伝子変異: {gene_mutation_text}\n",
"Meseable tumor: {meseable_text}\n",
"Biopsiable tumor: {biopsiable_text}\n",
"です。\n",
"\"\"\"\n",
" return ex_question"
]
},
{
"cell_type": "code",
"execution_count": 5,
"metadata": {},
"outputs": [],
"source": [
"def generate_ex_question_English(age, sex, tumor_type, GeneMutation, Meseable, Biopsiable):\n",
" # GeneMutationが空の場合は\"Unknown\"に設定\n",
" gene_mutation_text = GeneMutation if GeneMutation else \"Unknown\"\n",
" \n",
" # sexの値を male または female に変換\n",
" sex_text = \"male\" if sex == \"男性\" else \"female\" if sex == \"女性\" else \"Unknown\"\n",
" \n",
" # MeseableとBiopsiableの値を \"Yes\", \"No\", \"Unknown\" に変換\n",
" meseable_text = (\n",
" \"Yes\" if Meseable == \"有り\" else \"No\" if Meseable == \"無し\" else \"Unknown\"\n",
" )\n",
" biopsiable_text = (\n",
" \"Yes\" if Biopsiable == \"有り\" else \"No\" if Biopsiable == \"無し\" else \"Unknown\"\n",
" )\n",
" \n",
" # 英語での質問文を生成\n",
" ex_question = f\"\"\"Can a {age}-year-old {sex_text} patient with {tumor_type} participate in this clinical trial?\n",
"Known gene mutation: {gene_mutation_text}\n",
"Measurable tumor: {meseable_text}\n",
"Biopsiable tumor: {biopsiable_text}\n",
"\"\"\"\n",
" return ex_question\n"
]
},
{
"cell_type": "code",
"execution_count": 6,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"Stomach cancer\n"
]
}
],
"source": [
"#Define extractor\n",
"Translator = LLMTranslator(groq)\n",
"TumorName = Translator.translate(tumor_type)\n",
"print(TumorName)"
]
},
{
"cell_type": "code",
"execution_count": 7,
"metadata": {},
"outputs": [],
"source": [
"TumorName = \"gastric cancer\""
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
},
{
"cell_type": "code",
"execution_count": 8,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"'Can a 65-year-old male patient with gastric cancer participate in this clinical trial?\\nKnown gene mutation: HER2\\nMeasurable tumor: Yes\\nBiopsiable tumor: Yes\\n'"
]
},
"execution_count": 8,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"ex_question = generate_ex_question_English(age, sex, TumorName, GeneMutation, Meseable, Biopsiable)\n",
"ex_question"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"ex_question = \"\"\"\"65歳男性の胃癌患者さんはこの治験に参加することができますか？\n",
"判明している遺伝子変異:HER2\n",
"Meseable tumor:Yes\n",
"biopsiable tumor: Yes\n",
"です。\n",
"\"\"\""
]
},
{
"cell_type": "code",
"execution_count": 9,
"metadata": {},
"outputs": [],
"source": [
"#ex_question = \"65歳男性でが参加できる臨床治験を教えて下さい。\""
]
},
{
"cell_type": "code",
"execution_count": 10,
"metadata": {},
"outputs": [],
"source": [
"#ex_question = \"65歳男性でBRCA遺伝子の変異がある前立患者さんが参加できる臨床治験を教えて下さい。\""
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"modifierEnglish = QuestionModifierEnglish(groq)\n",
"modifierEnglish.modify_question(ex_question)"
]
},
{
"cell_type": "code",
"execution_count": 11,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.titles=gastric cancer SEARCH[Location](AREA[LocationCountry]Japan AND AREA[LocationStatus]Recruiting)&pageSize=100\n"
]
}
],
"source": [
"#Make db\n",
"df = fetch_clinical_trials(TumorName)\n",
"# 新しい列を追加\n",
"df['AgentJudgment'] = None\n",
"df['AgentGrade'] = None\n",
"#df = df.iloc[:5, :]\n",
"NCTIDs = list(df['NCTID' ])\n"
]
},
{
"cell_type": "code",
"execution_count": 12,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>NCTID</th>\n",
" <th>Title</th>\n",
" <th>Primary Completion Date</th>\n",
" <th>Cancer</th>\n",
" <th>Summary</th>\n",
" <th>Japanes Locations</th>\n",
" <th>Eligibility Criteria</th>\n",
" <th>AgentJudgment</th>\n",
" <th>AgentGrade</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>NCT03505320</td>\n",
" <td>A Study of Zolbetuximab (IMAB362) in Adults Wi...</td>\n",
" <td>2025-04-30</td>\n",
" <td>Pharmacokinetics of Zolbetuximab, Gastric Canc...</td>\n",
" <td>Zolbetuximab is being studied as a treatment f...</td>\n",
" <td>Chiba, Tokyo</td>\n",
" <td>Inclusion Criteria:\\n\\n* Female subject eligib...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1</th>\n",
" <td>NCT05002127</td>\n",
" <td>A Study of Evorpacept (ALX148) in Patients wit...</td>\n",
" <td>2026-07</td>\n",
" <td>Gastric Cancer, Gastroesophageal Junction Aden...</td>\n",
" <td>A Phase 2/3 Study of Evorpacept (ALX148) in Co...</td>\n",
" <td>Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasak...</td>\n",
" <td>Inclusion Criteria:\\n\\n* HER2-overexpressing a...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>2</th>\n",
" <td>NCT05365581</td>\n",
" <td>A Study of ASP2138 Given by Itself or Given Wi...</td>\n",
" <td>2026-10-31</td>\n",
" <td>Gastric Adenocarcinoma, Gastroesophageal Junct...</td>\n",
" <td>Claudin 18.2 protein, or CLDN18.2 is a protein...</td>\n",
" <td>Kashiwa, Nagoya, Osakasayama, Suita, Yokohama, ku</td>\n",
" <td>Inclusion Criteria:\\n\\n* Participant is consid...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3</th>\n",
" <td>NCT05111626</td>\n",
" <td>Bemarituzumab Plus Chemotherapy and Nivolumab ...</td>\n",
" <td>2026-09-26</td>\n",
" <td>Gastric Cancer, Gastroesophageal Junction Aden...</td>\n",
" <td>The main objective of Part 1 is to evaluate th...</td>\n",
" <td>Sapporo, gun, ku, shi</td>\n",
" <td>Inclusion Criteria Part 1 and Part 2:\\n\\n* Adu...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4</th>\n",
" <td>NCT06324357</td>\n",
" <td>Beamion BCGC-1: A Study to Find a Suitable Dos...</td>\n",
" <td>2027-02-22</td>\n",
" <td>Metastatic Breast Cancer, Metastatic Gastric A...</td>\n",
" <td>This study is open to adults aged 18 years and...</td>\n",
" <td>ku, shi</td>\n",
" <td>Inclusion Criteria:\\n\\n* Signed and dated writ...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>5</th>\n",
" <td>NCT06056024</td>\n",
" <td>A Study to Test How Well Different Doses of BI...</td>\n",
" <td>2027-05-26</td>\n",
" <td>Solid Tumor, KRAS Mutation</td>\n",
" <td>This study is open to adults with advanced can...</td>\n",
" <td>Kashiwa, ku</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Patients with pathol...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>6</th>\n",
" <td>NCT04379596</td>\n",
" <td>Ph1b/2 Study of the Safety and Efficacy of T-D...</td>\n",
" <td>2026-07-30</td>\n",
" <td>Gastric Cancer</td>\n",
" <td>DESTINY-Gastric03 will investigate the safety,...</td>\n",
" <td>Kashiwa, gun, ku, shi</td>\n",
" <td>Inclusion criteria:\\n\\n1. Male and female part...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>NCT00197470</td>\n",
" <td>Cytokine Gene Polymorphisms in Gastric Diseases</td>\n",
" <td>Unknown Date</td>\n",
" <td>Gastric Ulcer, Duodenal Ulcer, Gastric Cancer</td>\n",
" <td>Recently, cytokine polymorphisms are considere...</td>\n",
" <td>Hamamatsu</td>\n",
" <td>Inclusion Criteria:\\n\\n-\\n\\nExclusion Criteria...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>8</th>\n",
" <td>NCT05205343</td>\n",
" <td>Trans-Pacific Multicenter Collaborative Study ...</td>\n",
" <td>2026-05-31</td>\n",
" <td>Gastrostomy, Gastric, GastroEsophageal Cancer</td>\n",
" <td>To compare the symptoms of patients who have a...</td>\n",
" <td>Tokyo</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Able to speak and re...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>9</th>\n",
" <td>NCT06490055</td>\n",
" <td>Predicting the Efficacy in Advanced Gastric Ca...</td>\n",
" <td>2025-12-31</td>\n",
" <td>Gastric Cancer, Chemotherapy Effect, Paclitaxe...</td>\n",
" <td>With advances in chemotherapy for gastric canc...</td>\n",
" <td>Kurashiki</td>\n",
" <td>Inclusion Criteria:\\n\\n1. unresectable or recu...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>10</th>\n",
" <td>NCT06490159</td>\n",
" <td>Predicting Peripheral Neuropathy of Paclitaxel...</td>\n",
" <td>2025-12-31</td>\n",
" <td>Gastric Cancer, Chemotherapy-induced Periphera...</td>\n",
" <td>Although advances in chemotherapy have improve...</td>\n",
" <td>Kurashiki</td>\n",
" <td>Inclusion Criteria:\\n\\n1. unresectable or recu...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>11</th>\n",
" <td>NCT05438459</td>\n",
" <td>GAIA-102 Intraperitoneal Administration in Pat...</td>\n",
" <td>2026-12-31</td>\n",
" <td>Gastric Cancer, Pancreatic Cancer</td>\n",
" <td>Phase I Part :\\n\\nConfirm the safety of GAIA-1...</td>\n",
" <td>shi</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Unresectable, advanc...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>NCT04745988</td>\n",
" <td>An Open Label Phase 2 Study to Evaluate the Sa...</td>\n",
" <td>2025-08</td>\n",
" <td>Gastric Cancer</td>\n",
" <td>This study is an open label phase 2 study to e...</td>\n",
" <td>Kashiwa</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Have gastric and gas...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>13</th>\n",
" <td>NCT06038578</td>\n",
" <td>A Study of TRK-950 When Used in Combination Wi...</td>\n",
" <td>2025-08-31</td>\n",
" <td>Gastric Adenocarcinoma, Gastric Cancer, Gastro...</td>\n",
" <td>This study will assess the efficacy, safety, o...</td>\n",
" <td>Chuo Ku, Kashiwa, Ku</td>\n",
" <td>Inclusion Criteria:\\n\\n* Histologically or cyt...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>14</th>\n",
" <td>NCT05322577</td>\n",
" <td>A Study Evaluating Bemarituzumab in Combinatio...</td>\n",
" <td>2026-03-17</td>\n",
" <td>Gastric Cancer, Gastroesophageal Junction Cancer</td>\n",
" <td>The main objectives of this study are to evalu...</td>\n",
" <td>Shi, gun, ku, shi</td>\n",
" <td>Inclusion Criteria:\\n\\n* Adults with unresecta...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>15</th>\n",
" <td>NCT05152147</td>\n",
" <td>A Study of Zanidatamab in Combination With Che...</td>\n",
" <td>2024-12-31</td>\n",
" <td>Gastric Neoplasms, Gastroesophageal Adenocarci...</td>\n",
" <td>This study is being done to find out if zanida...</td>\n",
" <td>Cho, Chuo Ku, Hirakata, Ina, Ku, Matsuyama, Na...</td>\n",
" <td>Inclusion Criteria:\\n\\n* Histologically confir...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"</div>"
],
"text/plain": [
" NCTID Title \\\n",
"0 NCT03505320 A Study of Zolbetuximab (IMAB362) in Adults Wi... \n",
"1 NCT05002127 A Study of Evorpacept (ALX148) in Patients wit... \n",
"2 NCT05365581 A Study of ASP2138 Given by Itself or Given Wi... \n",
"3 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab ... \n",
"4 NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dos... \n",
"5 NCT06056024 A Study to Test How Well Different Doses of BI... \n",
"6 NCT04379596 Ph1b/2 Study of the Safety and Efficacy of T-D... \n",
"7 NCT00197470 Cytokine Gene Polymorphisms in Gastric Diseases \n",
"8 NCT05205343 Trans-Pacific Multicenter Collaborative Study ... \n",
"9 NCT06490055 Predicting the Efficacy in Advanced Gastric Ca... \n",
"10 NCT06490159 Predicting Peripheral Neuropathy of Paclitaxel... \n",
"11 NCT05438459 GAIA-102 Intraperitoneal Administration in Pat... \n",
"12 NCT04745988 An Open Label Phase 2 Study to Evaluate the Sa... \n",
"13 NCT06038578 A Study of TRK-950 When Used in Combination Wi... \n",
"14 NCT05322577 A Study Evaluating Bemarituzumab in Combinatio... \n",
"15 NCT05152147 A Study of Zanidatamab in Combination With Che... \n",
"\n",
" Primary Completion Date Cancer \\\n",
"0 2025-04-30 Pharmacokinetics of Zolbetuximab, Gastric Canc... \n",
"1 2026-07 Gastric Cancer, Gastroesophageal Junction Aden... \n",
"2 2026-10-31 Gastric Adenocarcinoma, Gastroesophageal Junct... \n",
"3 2026-09-26 Gastric Cancer, Gastroesophageal Junction Aden... \n",
"4 2027-02-22 Metastatic Breast Cancer, Metastatic Gastric A... \n",
"5 2027-05-26 Solid Tumor, KRAS Mutation \n",
"6 2026-07-30 Gastric Cancer \n",
"7 Unknown Date Gastric Ulcer, Duodenal Ulcer, Gastric Cancer \n",
"8 2026-05-31 Gastrostomy, Gastric, GastroEsophageal Cancer \n",
"9 2025-12-31 Gastric Cancer, Chemotherapy Effect, Paclitaxe... \n",
"10 2025-12-31 Gastric Cancer, Chemotherapy-induced Periphera... \n",
"11 2026-12-31 Gastric Cancer, Pancreatic Cancer \n",
"12 2025-08 Gastric Cancer \n",
"13 2025-08-31 Gastric Adenocarcinoma, Gastric Cancer, Gastro... \n",
"14 2026-03-17 Gastric Cancer, Gastroesophageal Junction Cancer \n",
"15 2024-12-31 Gastric Neoplasms, Gastroesophageal Adenocarci... \n",
"\n",
" Summary \\\n",
"0 Zolbetuximab is being studied as a treatment f... \n",
"1 A Phase 2/3 Study of Evorpacept (ALX148) in Co... \n",
"2 Claudin 18.2 protein, or CLDN18.2 is a protein... \n",
"3 The main objective of Part 1 is to evaluate th... \n",
"4 This study is open to adults aged 18 years and... \n",
"5 This study is open to adults with advanced can... \n",
"6 DESTINY-Gastric03 will investigate the safety,... \n",
"7 Recently, cytokine polymorphisms are considere... \n",
"8 To compare the symptoms of patients who have a... \n",
"9 With advances in chemotherapy for gastric canc... \n",
"10 Although advances in chemotherapy have improve... \n",
"11 Phase I Part :\\n\\nConfirm the safety of GAIA-1... \n",
"12 This study is an open label phase 2 study to e... \n",
"13 This study will assess the efficacy, safety, o... \n",
"14 The main objectives of this study are to evalu... \n",
"15 This study is being done to find out if zanida... \n",
"\n",
" Japanes Locations \\\n",
"0 Chiba, Tokyo \n",
"1 Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasak... \n",
"2 Kashiwa, Nagoya, Osakasayama, Suita, Yokohama, ku \n",
"3 Sapporo, gun, ku, shi \n",
"4 ku, shi \n",
"5 Kashiwa, ku \n",
"6 Kashiwa, gun, ku, shi \n",
"7 Hamamatsu \n",
"8 Tokyo \n",
"9 Kurashiki \n",
"10 Kurashiki \n",
"11 shi \n",
"12 Kashiwa \n",
"13 Chuo Ku, Kashiwa, Ku \n",
"14 Shi, gun, ku, shi \n",
"15 Cho, Chuo Ku, Hirakata, Ina, Ku, Matsuyama, Na... \n",
"\n",
" Eligibility Criteria AgentJudgment AgentGrade \n",
"0 Inclusion Criteria:\\n\\n* Female subject eligib... None None \n",
"1 Inclusion Criteria:\\n\\n* HER2-overexpressing a... None None \n",
"2 Inclusion Criteria:\\n\\n* Participant is consid... None None \n",
"3 Inclusion Criteria Part 1 and Part 2:\\n\\n* Adu... None None \n",
"4 Inclusion Criteria:\\n\\n* Signed and dated writ... None None \n",
"5 Inclusion Criteria:\\n\\n1. Patients with pathol... None None \n",
"6 Inclusion criteria:\\n\\n1. Male and female part... None None \n",
"7 Inclusion Criteria:\\n\\n-\\n\\nExclusion Criteria... None None \n",
"8 Inclusion Criteria:\\n\\n1. Able to speak and re... None None \n",
"9 Inclusion Criteria:\\n\\n1. unresectable or recu... None None \n",
"10 Inclusion Criteria:\\n\\n1. unresectable or recu... None None \n",
"11 Inclusion Criteria:\\n\\n1. Unresectable, advanc... None None \n",
"12 Inclusion Criteria:\\n\\n1. Have gastric and gas... None None \n",
"13 Inclusion Criteria:\\n\\n* Histologically or cyt... None None \n",
"14 Inclusion Criteria:\\n\\n* Adults with unresecta... None None \n",
"15 Inclusion Criteria:\\n\\n* Histologically confir... None None "
]
},
"execution_count": 12,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df"
]
},
{
"cell_type": "code",
"execution_count": 13,
"metadata": {},
"outputs": [],
"source": [
"\n",
"#Define agents\n",
"#modifier = QuestionModifierEnglish(groq)\n",
"CriteriaCheckAgent = SimpleClinicalTrialAgent(groq)\n",
"grader_agent = GraderAgent(groq)"
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
},
{
"cell_type": "code",
"execution_count": 14,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"The patient is not eligible for this clinical trial because the inclusion criteria specify that female subjects are eligible, and the patient is a 65-year-old male.\n",
"no\n",
"The patient is eligible for this clinical trial based on the provided information, as he has a measurable and biopsiable tumor with a known HER2 gene mutation, which meets the inclusion criteria. However, I do not know if he has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy, which is also required for inclusion.\n",
"unclear\n",
"The patient is eligible for this clinical trial based on the provided criteria. The patient meets the inclusion criteria, including having a measurable tumor, being at least 18 years old, and having a predicted life expectancy of at least 12 weeks. The patient also has histologically confirmed gastric/gastroesophageal junction (GEJ) adenocarcinoma, which is one of the specified disease types for this trial. Additionally, the patient has a HER2-positive tumor, which is not an exclusion criterion for this trial.\n",
"yes\n",
"The patient is eligible for this clinical trial based on the provided criteria, as they meet the inclusion criteria for age, measurable tumor, and biopsiable tumor. However, the patient's HER2 status is known to be positive, which is an exclusion criterion. Therefore, the patient is not eligible for this clinical trial.\n",
"no\n",
"The patient is not eligible for this clinical trial because the trial is for metastatic breast cancer (mBC) or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma (mGEAC), and the patient has gastric cancer, which is not specified as an eligible type of cancer.\n",
"no\n",
"The patient is not eligible for this clinical trial because the trial requires a KRAS wild type (wt) amplification or a KRAS G12V mutation, but the patient has a HER2 gene mutation.\n",
"no\n",
"The patient is eligible for this clinical trial based on the provided criteria, as they meet the inclusion criteria (age, disease characteristics, measurable tumor, and HER2-positive status) and do not have any of the exclusion criteria mentioned.\n",
"yes\n",
"I do not know if the patient is eligible for this clinical trial because the criteria do not mention age or specific types of cancer, and there is no information about H. pylori status in the patient.\n",
"unclear\n",
"The patient is eligible for this clinical trial based on the provided criteria, as he has a biopsy-confirmed diagnosis of gastric cancer, is 65 years old (meeting the age criterion), and there is no mention of any exclusion criteria being met.\n",
"yes\n",
"The patient is eligible for this clinical trial based on the provided information, as he meets the inclusion criteria (age, measurable tumor, biopsiable tumor, and gastric cancer diagnosis) and does not appear to meet any of the exclusion criteria.\n",
"yes\n",
"The patient is eligible for this clinical trial based on the provided criteria, as they meet the inclusion criteria (age, measurable tumor, biopsiable tumor, and gastric cancer diagnosis) and do not have any of the listed exclusion criteria.\n",
"yes\n",
"Based on the provided criteria, the 65-year-old male patient with gastric cancer and a known HER2 gene mutation appears to be eligible for this clinical trial, as he meets the inclusion criteria (e.g., unresectable advanced gastric cancer, measurable tumor, biopsiable tumor, etc.) and does not have any obvious exclusion criteria mentioned. However, I would need to review the patient's full medical history and current condition to confirm eligibility.\n",
"unclear\n",
"The patient is eligible for this clinical trial based on the provided criteria, as they meet the inclusion criteria (gastric cancer, measurable tumor, biopsiable tumor, age ≥ 20, etc.) and do not have any of the exclusion criteria mentioned.\n",
"yes\n",
"The patient is not eligible for this clinical trial because the patient has a known HER2 gene mutation, and the exclusion criteria specify that patients with HER2 positive gastric or GEJ adenocarcinoma are not eligible.\n",
"no\n",
"The patient is not eligible for this clinical trial because they have a known HER2 gene mutation, which is an exclusion criterion.\n",
"no\n",
"Based on the provided information, the 65-year-old male patient with gastric cancer and a known HER2 gene mutation appears to be eligible for this clinical trial, as he meets the inclusion criteria of having measurable tumor and biopsiable tumor, and there is no mention of any exclusion criteria that would disqualify him.\n",
"yes\n"
]
}
],
"source": [
"for nct_id in NCTIDs:\n",
" TargetCriteria = df.loc[df['NCTID'] == nct_id, 'Eligibility Criteria'].values[0]\n",
" AgentJudgment = CriteriaCheckAgent.evaluate_eligibility(TargetCriteria, ex_question)\n",
" print(AgentJudgment)\n",
"\n",
" AgentGrade = grader_agent.evaluate_eligibility(AgentJudgment)\n",
" print(AgentGrade)\n",
" # NCTIDに一致する行を見つけて更新\n",
" df.loc[df['NCTID'] == nct_id, 'AgentJudgment'] = AgentJudgment\n",
" df.loc[df['NCTID'] == nct_id, 'AgentGrade'] = AgentGrade\n"
]
},
{
"cell_type": "code",
"execution_count": 15,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>NCTID</th>\n",
" <th>Title</th>\n",
" <th>Primary Completion Date</th>\n",
" <th>Cancer</th>\n",
" <th>Summary</th>\n",
" <th>Japanes Locations</th>\n",
" <th>Eligibility Criteria</th>\n",
" <th>AgentJudgment</th>\n",
" <th>AgentGrade</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>NCT03505320</td>\n",
" <td>A Study of Zolbetuximab (IMAB362) in Adults Wi...</td>\n",
" <td>2025-04-30</td>\n",
" <td>Pharmacokinetics of Zolbetuximab, Gastric Canc...</td>\n",
" <td>Zolbetuximab is being studied as a treatment f...</td>\n",
" <td>Chiba, Tokyo</td>\n",
" <td>Inclusion Criteria:\\n\\n* Female subject eligib...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1</th>\n",
" <td>NCT05002127</td>\n",
" <td>A Study of Evorpacept (ALX148) in Patients wit...</td>\n",
" <td>2026-07</td>\n",
" <td>Gastric Cancer, Gastroesophageal Junction Aden...</td>\n",
" <td>A Phase 2/3 Study of Evorpacept (ALX148) in Co...</td>\n",
" <td>Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasak...</td>\n",
" <td>Inclusion Criteria:\\n\\n* HER2-overexpressing a...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>unclear</td>\n",
" </tr>\n",
" <tr>\n",
" <th>2</th>\n",
" <td>NCT05365581</td>\n",
" <td>A Study of ASP2138 Given by Itself or Given Wi...</td>\n",
" <td>2026-10-31</td>\n",
" <td>Gastric Adenocarcinoma, Gastroesophageal Junct...</td>\n",
" <td>Claudin 18.2 protein, or CLDN18.2 is a protein...</td>\n",
" <td>Kashiwa, Nagoya, Osakasayama, Suita, Yokohama, ku</td>\n",
" <td>Inclusion Criteria:\\n\\n* Participant is consid...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3</th>\n",
" <td>NCT05111626</td>\n",
" <td>Bemarituzumab Plus Chemotherapy and Nivolumab ...</td>\n",
" <td>2026-09-26</td>\n",
" <td>Gastric Cancer, Gastroesophageal Junction Aden...</td>\n",
" <td>The main objective of Part 1 is to evaluate th...</td>\n",
" <td>Sapporo, gun, ku, shi</td>\n",
" <td>Inclusion Criteria Part 1 and Part 2:\\n\\n* Adu...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4</th>\n",
" <td>NCT06324357</td>\n",
" <td>Beamion BCGC-1: A Study to Find a Suitable Dos...</td>\n",
" <td>2027-02-22</td>\n",
" <td>Metastatic Breast Cancer, Metastatic Gastric A...</td>\n",
" <td>This study is open to adults aged 18 years and...</td>\n",
" <td>ku, shi</td>\n",
" <td>Inclusion Criteria:\\n\\n* Signed and dated writ...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>5</th>\n",
" <td>NCT06056024</td>\n",
" <td>A Study to Test How Well Different Doses of BI...</td>\n",
" <td>2027-05-26</td>\n",
" <td>Solid Tumor, KRAS Mutation</td>\n",
" <td>This study is open to adults with advanced can...</td>\n",
" <td>Kashiwa, ku</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Patients with pathol...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>6</th>\n",
" <td>NCT04379596</td>\n",
" <td>Ph1b/2 Study of the Safety and Efficacy of T-D...</td>\n",
" <td>2026-07-30</td>\n",
" <td>Gastric Cancer</td>\n",
" <td>DESTINY-Gastric03 will investigate the safety,...</td>\n",
" <td>Kashiwa, gun, ku, shi</td>\n",
" <td>Inclusion criteria:\\n\\n1. Male and female part...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>NCT00197470</td>\n",
" <td>Cytokine Gene Polymorphisms in Gastric Diseases</td>\n",
" <td>Unknown Date</td>\n",
" <td>Gastric Ulcer, Duodenal Ulcer, Gastric Cancer</td>\n",
" <td>Recently, cytokine polymorphisms are considere...</td>\n",
" <td>Hamamatsu</td>\n",
" <td>Inclusion Criteria:\\n\\n-\\n\\nExclusion Criteria...</td>\n",
" <td>I do not know if the patient is eligible for t...</td>\n",
" <td>unclear</td>\n",
" </tr>\n",
" <tr>\n",
" <th>8</th>\n",
" <td>NCT05205343</td>\n",
" <td>Trans-Pacific Multicenter Collaborative Study ...</td>\n",
" <td>2026-05-31</td>\n",
" <td>Gastrostomy, Gastric, GastroEsophageal Cancer</td>\n",
" <td>To compare the symptoms of patients who have a...</td>\n",
" <td>Tokyo</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Able to speak and re...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>9</th>\n",
" <td>NCT06490055</td>\n",
" <td>Predicting the Efficacy in Advanced Gastric Ca...</td>\n",
" <td>2025-12-31</td>\n",
" <td>Gastric Cancer, Chemotherapy Effect, Paclitaxe...</td>\n",
" <td>With advances in chemotherapy for gastric canc...</td>\n",
" <td>Kurashiki</td>\n",
" <td>Inclusion Criteria:\\n\\n1. unresectable or recu...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>10</th>\n",
" <td>NCT06490159</td>\n",
" <td>Predicting Peripheral Neuropathy of Paclitaxel...</td>\n",
" <td>2025-12-31</td>\n",
" <td>Gastric Cancer, Chemotherapy-induced Periphera...</td>\n",
" <td>Although advances in chemotherapy have improve...</td>\n",
" <td>Kurashiki</td>\n",
" <td>Inclusion Criteria:\\n\\n1. unresectable or recu...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>11</th>\n",
" <td>NCT05438459</td>\n",
" <td>GAIA-102 Intraperitoneal Administration in Pat...</td>\n",
" <td>2026-12-31</td>\n",
" <td>Gastric Cancer, Pancreatic Cancer</td>\n",
" <td>Phase I Part :\\n\\nConfirm the safety of GAIA-1...</td>\n",
" <td>shi</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Unresectable, advanc...</td>\n",
" <td>Based on the provided criteria, the 65-year-ol...</td>\n",
" <td>unclear</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>NCT04745988</td>\n",
" <td>An Open Label Phase 2 Study to Evaluate the Sa...</td>\n",
" <td>2025-08</td>\n",
" <td>Gastric Cancer</td>\n",
" <td>This study is an open label phase 2 study to e...</td>\n",
" <td>Kashiwa</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Have gastric and gas...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>13</th>\n",
" <td>NCT06038578</td>\n",
" <td>A Study of TRK-950 When Used in Combination Wi...</td>\n",
" <td>2025-08-31</td>\n",
" <td>Gastric Adenocarcinoma, Gastric Cancer, Gastro...</td>\n",
" <td>This study will assess the efficacy, safety, o...</td>\n",
" <td>Chuo Ku, Kashiwa, Ku</td>\n",
" <td>Inclusion Criteria:\\n\\n* Histologically or cyt...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>14</th>\n",
" <td>NCT05322577</td>\n",
" <td>A Study Evaluating Bemarituzumab in Combinatio...</td>\n",
" <td>2026-03-17</td>\n",
" <td>Gastric Cancer, Gastroesophageal Junction Cancer</td>\n",
" <td>The main objectives of this study are to evalu...</td>\n",
" <td>Shi, gun, ku, shi</td>\n",
" <td>Inclusion Criteria:\\n\\n* Adults with unresecta...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>15</th>\n",
" <td>NCT05152147</td>\n",
" <td>A Study of Zanidatamab in Combination With Che...</td>\n",
" <td>2024-12-31</td>\n",
" <td>Gastric Neoplasms, Gastroesophageal Adenocarci...</td>\n",
" <td>This study is being done to find out if zanida...</td>\n",
" <td>Cho, Chuo Ku, Hirakata, Ina, Ku, Matsuyama, Na...</td>\n",
" <td>Inclusion Criteria:\\n\\n* Histologically confir...</td>\n",
" <td>Based on the provided information, the 65-year...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"</div>"
],
"text/plain": [
" NCTID Title \\\n",
"0 NCT03505320 A Study of Zolbetuximab (IMAB362) in Adults Wi... \n",
"1 NCT05002127 A Study of Evorpacept (ALX148) in Patients wit... \n",
"2 NCT05365581 A Study of ASP2138 Given by Itself or Given Wi... \n",
"3 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab ... \n",
"4 NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dos... \n",
"5 NCT06056024 A Study to Test How Well Different Doses of BI... \n",
"6 NCT04379596 Ph1b/2 Study of the Safety and Efficacy of T-D... \n",
"7 NCT00197470 Cytokine Gene Polymorphisms in Gastric Diseases \n",
"8 NCT05205343 Trans-Pacific Multicenter Collaborative Study ... \n",
"9 NCT06490055 Predicting the Efficacy in Advanced Gastric Ca... \n",
"10 NCT06490159 Predicting Peripheral Neuropathy of Paclitaxel... \n",
"11 NCT05438459 GAIA-102 Intraperitoneal Administration in Pat... \n",
"12 NCT04745988 An Open Label Phase 2 Study to Evaluate the Sa... \n",
"13 NCT06038578 A Study of TRK-950 When Used in Combination Wi... \n",
"14 NCT05322577 A Study Evaluating Bemarituzumab in Combinatio... \n",
"15 NCT05152147 A Study of Zanidatamab in Combination With Che... \n",
"\n",
" Primary Completion Date Cancer \\\n",
"0 2025-04-30 Pharmacokinetics of Zolbetuximab, Gastric Canc... \n",
"1 2026-07 Gastric Cancer, Gastroesophageal Junction Aden... \n",
"2 2026-10-31 Gastric Adenocarcinoma, Gastroesophageal Junct... \n",
"3 2026-09-26 Gastric Cancer, Gastroesophageal Junction Aden... \n",
"4 2027-02-22 Metastatic Breast Cancer, Metastatic Gastric A... \n",
"5 2027-05-26 Solid Tumor, KRAS Mutation \n",
"6 2026-07-30 Gastric Cancer \n",
"7 Unknown Date Gastric Ulcer, Duodenal Ulcer, Gastric Cancer \n",
"8 2026-05-31 Gastrostomy, Gastric, GastroEsophageal Cancer \n",
"9 2025-12-31 Gastric Cancer, Chemotherapy Effect, Paclitaxe... \n",
"10 2025-12-31 Gastric Cancer, Chemotherapy-induced Periphera... \n",
"11 2026-12-31 Gastric Cancer, Pancreatic Cancer \n",
"12 2025-08 Gastric Cancer \n",
"13 2025-08-31 Gastric Adenocarcinoma, Gastric Cancer, Gastro... \n",
"14 2026-03-17 Gastric Cancer, Gastroesophageal Junction Cancer \n",
"15 2024-12-31 Gastric Neoplasms, Gastroesophageal Adenocarci... \n",
"\n",
" Summary \\\n",
"0 Zolbetuximab is being studied as a treatment f... \n",
"1 A Phase 2/3 Study of Evorpacept (ALX148) in Co... \n",
"2 Claudin 18.2 protein, or CLDN18.2 is a protein... \n",
"3 The main objective of Part 1 is to evaluate th... \n",
"4 This study is open to adults aged 18 years and... \n",
"5 This study is open to adults with advanced can... \n",
"6 DESTINY-Gastric03 will investigate the safety,... \n",
"7 Recently, cytokine polymorphisms are considere... \n",
"8 To compare the symptoms of patients who have a... \n",
"9 With advances in chemotherapy for gastric canc... \n",
"10 Although advances in chemotherapy have improve... \n",
"11 Phase I Part :\\n\\nConfirm the safety of GAIA-1... \n",
"12 This study is an open label phase 2 study to e... \n",
"13 This study will assess the efficacy, safety, o... \n",
"14 The main objectives of this study are to evalu... \n",
"15 This study is being done to find out if zanida... \n",
"\n",
" Japanes Locations \\\n",
"0 Chiba, Tokyo \n",
"1 Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasak... \n",
"2 Kashiwa, Nagoya, Osakasayama, Suita, Yokohama, ku \n",
"3 Sapporo, gun, ku, shi \n",
"4 ku, shi \n",
"5 Kashiwa, ku \n",
"6 Kashiwa, gun, ku, shi \n",
"7 Hamamatsu \n",
"8 Tokyo \n",
"9 Kurashiki \n",
"10 Kurashiki \n",
"11 shi \n",
"12 Kashiwa \n",
"13 Chuo Ku, Kashiwa, Ku \n",
"14 Shi, gun, ku, shi \n",
"15 Cho, Chuo Ku, Hirakata, Ina, Ku, Matsuyama, Na... \n",
"\n",
" Eligibility Criteria \\\n",
"0 Inclusion Criteria:\\n\\n* Female subject eligib... \n",
"1 Inclusion Criteria:\\n\\n* HER2-overexpressing a... \n",
"2 Inclusion Criteria:\\n\\n* Participant is consid... \n",
"3 Inclusion Criteria Part 1 and Part 2:\\n\\n* Adu... \n",
"4 Inclusion Criteria:\\n\\n* Signed and dated writ... \n",
"5 Inclusion Criteria:\\n\\n1. Patients with pathol... \n",
"6 Inclusion criteria:\\n\\n1. Male and female part... \n",
"7 Inclusion Criteria:\\n\\n-\\n\\nExclusion Criteria... \n",
"8 Inclusion Criteria:\\n\\n1. Able to speak and re... \n",
"9 Inclusion Criteria:\\n\\n1. unresectable or recu... \n",
"10 Inclusion Criteria:\\n\\n1. unresectable or recu... \n",
"11 Inclusion Criteria:\\n\\n1. Unresectable, advanc... \n",
"12 Inclusion Criteria:\\n\\n1. Have gastric and gas... \n",
"13 Inclusion Criteria:\\n\\n* Histologically or cyt... \n",
"14 Inclusion Criteria:\\n\\n* Adults with unresecta... \n",
"15 Inclusion Criteria:\\n\\n* Histologically confir... \n",
"\n",
" AgentJudgment AgentGrade \n",
"0 The patient is not eligible for this clinical ... no \n",
"1 The patient is eligible for this clinical tria... unclear \n",
"2 The patient is eligible for this clinical tria... yes \n",
"3 The patient is eligible for this clinical tria... no \n",
"4 The patient is not eligible for this clinical ... no \n",
"5 The patient is not eligible for this clinical ... no \n",
"6 The patient is eligible for this clinical tria... yes \n",
"7 I do not know if the patient is eligible for t... unclear \n",
"8 The patient is eligible for this clinical tria... yes \n",
"9 The patient is eligible for this clinical tria... yes \n",
"10 The patient is eligible for this clinical tria... yes \n",
"11 Based on the provided criteria, the 65-year-ol... unclear \n",
"12 The patient is eligible for this clinical tria... yes \n",
"13 The patient is not eligible for this clinical ... no \n",
"14 The patient is not eligible for this clinical ... no \n",
"15 Based on the provided information, the 65-year... yes "
]
},
"execution_count": 15,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df"
]
},
{
"cell_type": "code",
"execution_count": 14,
"metadata": {},
"outputs": [],
"source": [
"df.to_csv('./65yerProstateCancer.csv')"
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|